Ribomic   Report issue

For profit Phase 2
Founded: Tokyo Japan (2003)

Organization Overview

First Clinical Trial
2018
NCT03633084
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ribomic USA | Ribomic USA Inc